Artivion, Inc. (NYSE:AORT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Artivion, Inc. (NYSE:AORT) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $44.8333.

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Canaccord Genuity Group increased their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Citigroup restated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st.

Artivion Stock Performance

NYSE:AORT opened at $23.38 on Friday. The business has a 50 day moving average of $26.30 and a 200 day moving average of $28.35. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -333.94 and a beta of 1.25. Artivion has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The business had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. On average, sell-side analysts predict that Artivion will post 0.45 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 11,480 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president directly owned 40,160 shares in the company, valued at $1,002,795.20. This trade represents a 22.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the transaction, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 90,460 shares of company stock worth $2,557,366. Company insiders own 6.30% of the company’s stock.

Institutional Trading of Artivion

A number of institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. grew its holdings in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC raised its holdings in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares during the last quarter. Quantbot Technologies LP bought a new stake in Artivion during the 2nd quarter valued at $103,000. Pictet Asset Management Holding SA raised its holdings in Artivion by 25.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,520 shares of the company’s stock valued at $202,000 after buying an additional 1,125 shares during the last quarter. Finally, R Squared Ltd boosted its position in Artivion by 29.5% during the 1st quarter. R Squared Ltd now owns 6,051 shares of the company’s stock valued at $222,000 after buying an additional 1,379 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.